Compare WFF & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WFF | NEUP |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.3M |
| IPO Year | 2025 | N/A |
| Metric | WFF | NEUP |
|---|---|---|
| Price | $0.43 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 202.8K | 75.6K |
| Earning Date | 12-31-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,021,079.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.45 | N/A |
| 52 Week Low | $0.41 | $3.00 |
| 52 Week High | $29.26 | $21.40 |
| Indicator | WFF | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 45.13 |
| Support Level | $0.43 | $3.82 |
| Resistance Level | $0.51 | $4.00 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 10.07 | 49.36 |
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.